7,500 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by APEIRON CAPITAL Ltd

APEIRON CAPITAL Ltd acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 7,500 shares of the company’s stock, valued at approximately $468,000. TransMedics Group accounts for approximately 0.2% of APEIRON CAPITAL Ltd’s holdings, making the stock its 13th largest holding.

A number of other hedge funds also recently bought and sold shares of the company. Principal Financial Group Inc. boosted its stake in TransMedics Group by 603.9% in the 2nd quarter. Principal Financial Group Inc. now owns 56,172 shares of the company’s stock worth $8,461,000 after purchasing an additional 48,192 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of TransMedics Group by 62.2% in the second quarter. Commonwealth Equity Services LLC now owns 6,497 shares of the company’s stock worth $979,000 after buying an additional 2,491 shares during the period. Rhumbline Advisers grew its holdings in shares of TransMedics Group by 3.9% during the second quarter. Rhumbline Advisers now owns 47,645 shares of the company’s stock valued at $7,176,000 after buying an additional 1,783 shares in the last quarter. Arizona State Retirement System raised its position in TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares during the period. Finally, Private Advisor Group LLC lifted its stake in TransMedics Group by 230.6% in the 2nd quarter. Private Advisor Group LLC now owns 10,017 shares of the company’s stock worth $1,509,000 after acquiring an additional 6,987 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TMDX has been the topic of several research analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

NASDAQ TMDX opened at $75.63 on Tuesday. TransMedics Group, Inc. has a fifty-two week low of $58.27 and a fifty-two week high of $177.37. The stock’s 50-day moving average is $75.83 and its two-hundred day moving average is $123.23. The firm has a market cap of $2.54 billion, a P/E ratio of 80.46 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the business posted ($0.12) earnings per share. The firm’s revenue was up 63.7% on a year-over-year basis. On average, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,459 shares of company stock valued at $1,802,244 over the last 90 days. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.